Welcome
Click here if you are not:
February 6, 2008 Archive
Certified for category 1 credit through February 6, 2010
Estimated time to complete: 1 hr
Instructions for participating in this CME activity:
- Read the journal article
- Review the slides and recorded audio of the program
- To receive CME credit, download and complete the evaluation form and return it to NCME via fax at 201-867-2491
ACCESS THE AUDIO PROGRAM IN 1 OF 3 WAYS:
TO DOWNLOAD THE JOURNAL ARTICLE CLICK ON THE TITLE BELOW
TO DOWNLOAD THE SLIDES CLICK HERE
Learning Objectives | Faculty Disclosures | Evaluation Link
Article Title:
Prospective Multicentric Randomized Phase III Study of Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors Comparing Interruption Versus Continuation of Treatment Beyond 1 Year: The French Sarcoma Group
(Click the name of the journal article to download the full text pdf)
Author:
Jean-Yves Blay, MD
Centre Leon Berard & Universite Claude Bernard
Lyon 1 & Unite d'Oncologie Medicale
Lyon, France
Publication
Issue Date:
Journal Clinical Oncology
2007
Moderator:
Jonathan C. Trent, MD, PhD
Assistant Professor of Medicine
Sarcoma Medical Oncology
The University of Texas MD
Anderson Cancer Center
Houston, Texas
After taking part in this activity, participants should be able to:
- Compare outcomes in patients with advanced gastrointestinal stromal tumors (GIST) undergoing continuous versus interrupted imatinib treatment beyond 1 year
- Review the potential problems that are associated with the chronic administration of imatinib
- Discuss the clinical implications of this study
Jean-Yves Blay, MD, PhD, has served as a consultant to GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Pfizer Inc, and Roche Laboratories Inc. and has received research support from Novartis Pharmaceuticals Corporation and Pfizer Inc.
Jonathan C, Trent, MD, PhD, reports no such relationships.
The NCME staff reports no financial relationships to disclose.
